ASAmol V. Shivange

Amol V. Shivange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amol V. Shivange has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands

    by Aaron L Nichols, Zack Blumenfeld, Chengcheng Fan, Laura Luebbert, Annet Em Blom, Bruce N Cohen, Jonathan S Marvin, Philip M Borden, Charlene H Kim, Anand K Muthusamy, et al.

    Nichols AL, Blumenfeld Z, Fan C, Luebbert L, Blom AEM, Cohen BN, Marvin JS, Borden PM, Kim CH, Muthusamy AK, Shivange AV, Knox HJ, Campello HR, Wang JH, Dougherty DA, Looger LL, Gallagher T, Rees DC, Lester HA. 2022. Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands. eLife 11:e74648. doi: 10.7554/eLife.74648.


  • Open Access

    Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands

    by Aaron L Nichols, Zack Blumenfeld, Chengcheng Fan, Laura Luebbert, Annet Em Blom, Bruce N Cohen, Jonathan S Marvin, Philip M Borden, Charlene H Kim, Anand K Muthusamy, et al.

    Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular and subcellular pharmacokinetic properties of these compounds in living cells. Here, we developed new intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) for the nicotinic partial agonists dianicline, cytisine, and two cytisine derivatives – 10-fluorocytisine and 9-bromo-10-ethylcytisine. We report the first atomic-scale structures of liganded periplasmic binding protein-based biosensors, accelerating development of iDrugSnFRs and also explaining the activation mechanism. The nicotinic iDrugSnFRs detect their drug partners in solution, as well as at the plasma membrane (PM) and in the endoplasmic reticulum (ER) of cell lines and mouse hippocampal neurons. At the PM, the speed of solution changes limits the growth and decay rates of the fluorescence response in almost all cases. In contrast, we found that rates of membrane crossing differ among these nicotinic drugs by >30-fold. The new nicotinic iDrugSnFRs provide insight into the real-time pharmacokinetic properties of nicotinic agonists and provide a methodology whereby iDrugSnFRs can inform both pharmaceutical neuroscience and addiction neuroscience.


  • Directed Evolution of a Selective and Sensitive Serotonin Sensor via Machine Learning

    by Elizabeth K. Unger, Jacob P. Keller, Michael Altermatt, Ruqiang Liang, Aya Matsui, Chunyang Dong, Olivia J. Hon, Zi Yao, Junqing Sun, Samba Banala, et al.


  • Open Access

    A fast genetically encoded fluorescent sensor for faithfulin vivoacetylcholine detection in mice, fish, worms and flies

    by Philip M. Borden, Peng Zhang, Amol V. Shivange, Jonathan S. Marvin, Joseph Cichon, Chuntao Dan, Kaspar Podgorski, Antonio Figueiredo, Ondrej Novak, Masashi Tanimoto, et al.

    Here we design and optimize a genetically encoded fluorescent indicator, iAChSnFR, for the ubiquitous neurotransmitter acetylcholine, based on a bacterial periplasmic binding protein. iAChSnFR shows large fluorescence changes, rapid rise and decay kinetics, and insensitivity to most cholinergic drugs. iAChSnFR revealed large transients in a variety of slice andin vivopreparations in mouse, fish, fly and worm. iAChSnFR will be useful for the study of acetylcholine in all animals.


  • Structure‐Guided Synthesis and Evaluation of Small‐Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain

    by Vadiraj Kurdekar, Saranya Giridharan, Jasti Subbarao, Mamatha B. Nijaguna, Jayaprakash Periasamy, Sanjana Boggaram, Amol V. Shivange, Gayathri Sadasivam, Muralidhara Padigaru, Vijay Potluri, et al.

    The tandem BRCT domains (tBRCT) of BRCA1 engage phosphoserine‐containing motifs in target proteins to propagate intracellular signals initiated by DNA damage, thereby controlling cell cycle arrest and DNA repair. Recently, we identified Bractoppin, the first small‐molecule inhibitor of the BRCA1 tBRCT domain, which selectively interrupts BRCA1‐mediated cellular responses evoked by DNA damage. Here, we combine structure‐guided chemical elaboration, protein mutagenesis and cellular assays to define the structural features responsible for Bractoppin's activity. Bractoppin fails to bind mutant forms of BRCA1 tBRCT bearing K1702A, a key residue mediating phosphopeptide recognition, or F1662R or L1701K that adjoin the pSer‐recognition site. However, the M1775R mutation, which engages the Phe residue in the consensus phosphopeptide motif pSer‐X‐X‐Phe, does not affect Bractoppin binding, confirming a binding mode distinct from the substrate phosphopeptide binding. We explored these structural features through structure‐guided chemical elaboration and characterized structure–activity relationships (SARs) in biochemical assays. Two analogues, CCBT2088 and CCBT2103 were effective in abrogating BRCA1 foci formation and inhibiting G2 arrest induced by irradiation of cells. Collectively, our findings reveal structural features underlying the activity of a novel inhibitor of phosphopeptide recognition by the BRCA1 tBRCT domain, providing fresh insights to guide the development of inhibitors that target protein–protein interactions.


  • Open Access

    Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors

    by Amol V. Shivange, Philip M. Borden, Anand K. Muthusamy, Aaron L. Nichols, Kallol Bera, Huan Bao, Ishak Bishara, Janice Jeon, Matthew J. Mulcahy, Bruce Cohen, et al.

    Nicotine dependence is thought to arise in part because nicotine permeates into the endoplasmic reticulum (ER), where it binds to nicotinic receptors (nAChRs) and begins an “inside-out” pathway that leads to up-regulation of nAChRs on the plasma membrane. However, the dynamics of nicotine entry into the ER are unquantified. Here, we develop a family of genetically encoded fluorescent biosensors for nicotine, termed iNicSnFRs. The iNicSnFRs are fusions between two proteins: a circularly permutated GFP and a periplasmic choline-/betaine-binding protein engineered to bind nicotine. The biosensors iNicSnFR3a and iNicSnFR3b respond to nicotine by increasing fluorescence at [nicotine] 75%. Reducing nicotine intake by 10-fold decreases activation to ∼20%. iNicSnFR3a and iNicSnFR3b also sense the smoking cessation drug varenicline, revealing that varenicline also permeates into the ER within seconds. Our iNicSnFRs enable optical subcellular pharmacokinetics for nicotine and varenicline during an early event in the inside-out pathway.


  • Microscopy Using Fluorescent Drug Biosensors for “Inside-Out Pharmacology”

    by Anand K. Muthusamy, Amol V. Shivange, Aaron L. Nichols, Aron Kamajaya, Janice Jeon, Philip M. Borden, Jonathan S. Marvin, Elizabeth K. Unger, Huan Bao, Edwin R. Chapman, et al.


  • Open Access

    Protein Consensus-Based Surface Engineering (ProCoS): A Computer-Assisted Method for Directed Protein Evolution

    by Amol V. Shivange, Hans Wolfgang Hoeffken, Stefan Haefner, Ulrich Schwaneberg

    Protein consensus-based surface engineering (ProCoS) is a simple and efficient method for directed protein evolution combining computational analysis and molecular biology tools to engineer protein ...


  • Iterative key-residues interrogation of a phytase with thermostability increasing substitutions identified in directed evolution

    by Amol V. Shivange, Danilo Roccatano, Ulrich Schwaneberg

    Bacterial phytases have attracted industrial interest as animal feed supplement due to their high activity and sufficient thermostability (required for feed pelleting). We devised an approach named KeySIDE, an iterative Key-residues interrogation of the wild type with Substitutions Identified in Directed Evolution for improving Yersinia mollaretii phytase (Ymphytase) thermostability by combining key beneficial substitutions and elucidating their individual roles. Directed evolution yielded in a discovery of nine positions in Ymphytase and combined iteratively to identify key positions. The “best” combination (M6: T77K, Q154H, G187S, and K289Q) resulted in significantly improved thermal resistance; the residual activity improved from 35 % (wild type) to 89 % (M6) at 58 °C and 20-min incubation. Melting temperature increased by 3 °C in M6 without a loss of specific activity. Molecular dynamics simulation studies revealed reduced flexibility in the loops located next to helices (B, F, and K) which possess substitutions (Helix-B: T77K, Helix-F: G187S, and Helix-K: K289E/Q). Reduced flexibility in the loops might be caused by strengthened hydrogen bonding network (e.g., G187S and K289E/K289Q) and a salt bridge (T77K). Our results demonstrate a promising approach to design phytases in food research, and we hope that the KeySIDE might become an attractive approach for understanding of structure–function relationships of enzymes.